AI drug development

GEn1E Lifesciences is a clinical-stage, Phase 2 company accelerating first-in-class precision therapies for inflammatory and rare diseases. It discovered a new binding pocket and developed a unique, validated mechanism of action for Dual Signal Modulators targeting kinase dysregulation (p38, MK2, ERK). Its GRID AI platform supports its drug development. It received US FDA Orphan Drug and Rare Pediatric Disease designations for a dual signal modulator for Duchenne Muscular Dystrophy.

Read more

clinical stage drug developmentkinase-targeted drug discovery